BioPharmSignal logoBioPharmSignal

Biotech News

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Bluejay Diagnostics (BJDX)Bluejay DiagnosticsConference / presentation

New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient

Related news

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BRLIBio-Reference Laboratories2026-09-08 17:55 EST

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

DGXQuest Diagnostics2026-08-25 13:30 EST

Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference

DGXQuest Diagnostics2026-08-24 13:00 EST

Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

LUCDLucid Diagnostics2026-04-09 12:01 EST

Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

BDSXBiodesix2026-08-04 10:00 EST

Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference

BIAFbioAffinity Technologies, Inc.2026-09-03 20:30 EST

bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

INBSIntelligent Bio Solutions2026-06-04 12:30 EST

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

View all latest news

Bluejay Diagnostics

Critical-Care Diagnostics Bluejay Diagnostics develops rapid blood tests for hospital and critical-care settings using its Symphony diagnostic platform. Symphony Platform Symphony is an automated, near-patient testing system designed to provide quantitative biomarker results without relying on a central laboratory workflow. Symphony IL-6...

Recent company news

BJDXBluejay Diagnostics2026-09-08 10:30 EST

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

BJDXBluejay Diagnostics2026-08-13 10:00 EST

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Stock data

Close
0.85 USD
Market cap
4.49M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States